EFFICIENCY AND SAFETY OF USE OF CANAGLIFLOZIN IN THE OUTPATIENT PRACTICE
- Autores: Demidov N.A1, Antsiferov M.B2, Dorofeeva L.G2
-
Afiliações:
- SBHCI Hospital “Kuznechiki" of Moscow Healthcare Department
- SBHCI «Endocrinological Dispensary» of Moscow Healthcare Department
- Edição: Nº 5 (2017)
- Páginas: 14-20
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289801
- ID: 289801
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article presents the results of evaluation of the efficacy and safety of the use of cannagliflozin at doses of 100 and 300 mg in outpatient practice. The use of cannagliflozin at doses of 100 and 300 mg resulted in a statistically significant improvement in carbohydrate metabolism, weight loss, blood pressure, and lipid profile. There was a statistically significant dose-dependent effect on the improvement of carbohydrate metabolism. Side effects more often manifested in the form of an increase in the frequency of urination and the amount of daily urine, much less often in the form of genital infections and, as a rule, did not cause the discontinuation of treatment or refusal of drug intake.
Texto integral
Sobre autores
N. Demidov
SBHCI Hospital “Kuznechiki" of Moscow Healthcare Department
Email: nicolay13@mail.ru
PhD, Chief Endocrinologist of the Troitsk and Novomoskovsk Administrative District of Moscow
M. Antsiferov
SBHCI «Endocrinological Dispensary» of Moscow Healthcare Department
L. Dorofeeva
SBHCI «Endocrinological Dispensary» of Moscow Healthcare Department
Bibliografia
- Алгоритмы специализированной медицинской помощи больным сахарным диабетом/ Под ред. И.И Дедова, М.В. Шестаковой, 7-й выпуск, М., 2015.
- Atlas IDF. 2015, www.diabetatlas.org.
- Sha S., Devineni D., Ghosh A., et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes. Metab. 2011;13:669-72.
- Rahmoune H., Thompson P.W., Ward J.M., Smith C.D., et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427-34.
- Leiter L.A., Yoon K.-H., Arias P Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Care. 2015;38:355-64.
- Nisly S.A., Kolanczyk D.M., Walton A.M. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. Am. J. Health Syst. Pharm. 2013;70:11-9.
- Haas B., Eckstein N., Pfeifer V., Mayer P., Hass M.D.S. Efficacy, safetyandregulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr. Diabetes. 2014;4(11):e143.
- Polidori D., Sha S., Mudaliar S. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion. Diabetes Care. 2013;36:2154-61.
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity and Metabolism. 2013;15:372-82.
- Cefalu W.T., Leiter L.A., Yoon K.-H., Arias P., Niskanen L. Efficacy and safety of canaglilozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382:941-50.
Arquivos suplementares
